重大公告
Announcement of phase II clinical trial result for ovarian cancer on OBI and Mackay Memorial Hospital cooperated Adagloxad Simolenin, OBI-822
Date of occurrence of the event: Sep 16, 2019 Company name: OBI Pharma, Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head …
Announcement on change of research and development officer
Type of personnel changed (please enter: spokesperson, acting spokesperson, important operational officer, financial officer, accounting officer, company secretary, research and development officer, or internal audit …
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase I/II Study of its Antibody-Drug Conjugate (ADC) targeted cancer therapy, OBI-999
Date of occurrence of the event: Aug 31, 2019 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head …
Board of Directors Approved the Change of Financial Officer and Acting Spokesperson
Type of personnel changed (please enter: spokesperson, acting spokesperson, important perational officer, financial officer, accounting officer, company secretary, research and development officer, or internal audit …
IND Phase I/II Human Clinical Trial Application of Globo-H Antibody-Drug Conjugate, OBI-999, submission to FDA
Date of occurrence of the event: Aug 03, 2019 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head …